Syngen Biotech Co.,Ltd. (TPEX:8279)
80.30
-0.20 (-0.25%)
Nov 13, 2026, 1:30 PM CST
Syngen Biotech Revenue
Syngen Biotech had revenue of 558.15M TWD in the quarter ending September 30, 2026, a decrease of -0.90%. This brings the company's total for the last twelve months to 2.05B, down -3.92% year-over-year. In the year 2025, Syngen Biotech had annual revenue of 2.14B with 6.10% growth. That makes Syngen Biotech the 26,330th largest company in the world by revenue and 1,212th in Taiwan.
Revenue (ttm)
2.05B
Revenue Growth
-3.92%
P/S Ratio
1.06
Revenue / Employee
8.29M
Employees
247
Market Cap
2.18B
Revenue by Geography
- Taiwan 2.02B 94.6%
- Others 115.70M 5.4%
Fiscal year ended Dec 31, 2025 See the full Syngen Biotech breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.14B | 122.89M | 6.10% |
| Dec 31, 2024 | 2.01B | 176.41M | 9.60% |
| Dec 31, 2023 | 1.84B | -93.41M | -4.84% |
| Dec 31, 2022 | 1.93B | 459.33M | 31.22% |
| Dec 31, 2021 | 1.47B | 159.83M | 12.19% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chunghwa Chemical Synthesis & Biotech | 934.29M |
| HeXun Biosciences | 308.21M |
| BioGend Therapeutics | 235.24M |
| G&E Herbal Biotechnology | 170.13M |
| 3D Global Biotech | 159.19M |
| Gwo Xi Stem Cell Applied Technology Co. , | 157.86M |
| Intech Biopharm | 54.34M |
| GlycoNex Incorporation | 22.21M |